Mastering CGM: Real Stories and Expert Tips for Seamless Glucose Monitoring
October 3, 2023
In the latest episode of Real Time Real Talk, we engage in an enlightening conversation on the progressive strides in diabetes management with our special guest, Dr. Nicholas Argento. With personal experience spanning over five decades of living with type one diabetes and leveraging his professional expertise in diabetes technology, Dr. Argento details the indispensable role that CGM plays in his life from diagnosis in 1968, the evolution of glucose monitoring, ie. From insulin to now integrating CGM with an automated insulin delivery devices and what the future could hold.
In this insightful discussion, Dr. Argento also offers his first-hand experience with the Dexcom G6 device, drawing parallels between CGM and a personal GPS for glucose. He elaborates on the downside of the traditional finger sticks method of monitoring blood glucose levels and champions the CGM as a significant milestone in diabetes management. He also shares actionable strategies for dietary adjustments and lifestyle modification, emphasizing the link between diet, light exercises, and effective blood glucose level management.
This is a fantastic episode with great takeaways, not just for those living with diabetes but also health care professionals.
This episode was recoded at ADA - The American Diabetes Association in July 2023.
Real-time real talk is intended for healthcare professionals in the US.
Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.
Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.
Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.
The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.
Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7.
Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products.
A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions.
Dr. Nicholas Argento MD, PhD is a paid spokesperson for Dexcom.
About Hello Dexcom
Dexcom Provider website
Warning: Do not use the Dexcom G7 CGM System or the Dexcom G6 System if you are on dialysis. The performance of these CGM systems has not been evaluated in this population and sensor readings may be inaccurate.
Brief Safety Statement
BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.
Dexcom Clarity Safety Information
The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.
Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.
References:
1. Breton MD, Kovatchev BP. One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology. Diabetes Technol Ther. 2021 Sep;23(9):601-608. doi: 10.1089/dia.2021.0097. Epub 2021 Apr 21. PMID: 33784196; PMCID: PMC8501470.
2. Tadej Battelino, et al; Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 1 August 2019; 42 (8): 1593–1603. https://doi.org/10.2337/dci19-0028
In the latest episode of Real Time Real Talk, we engage in an enlightening conversation on the progressive strides in diabetes management with our special guest, Dr. Nicholas Argento. With personal experience spanning over five decades of living with type one diabetes and leveraging his professional expertise in diabetes technology, Dr. Argento details the indispensable role that CGM plays in his life from diagnosis in 1968, the evolution of glucose monitoring, ie. From insulin to now integrating CGM with an automated insulin delivery devices and what the future could hold.
In this insightful discussion, Dr. Argento also offers his first-hand experience with the Dexcom G6 device, drawing parallels between CGM and a personal GPS for glucose. He elaborates on the downside of the traditional finger sticks method of monitoring blood glucose levels and champions the CGM as a significant milestone in diabetes management. He also shares actionable strategies for dietary adjustments and lifestyle modification, emphasizing the link between diet, light exercises, and effective blood glucose level management.
This is a fantastic episode with great takeaways, not just for those living with diabetes but also health care professionals.
This episode was recoded at ADA - The American Diabetes Association in July 2023.
Real-time real talk is intended for healthcare professionals in the US.
Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.
In this insightful discussion, Dr. Argento also offers his first-hand experience with the Dexcom G6 device, drawing parallels between CGM and a personal GPS for glucose. He elaborates on the downside of the traditional finger sticks method of monitoring blood glucose levels and champions the CGM as a significant milestone in diabetes management. He also shares actionable strategies for dietary adjustments and lifestyle modification, emphasizing the link between diet, light exercises, and effective blood glucose level management.
This is a fantastic episode with great takeaways, not just for those living with diabetes but also health care professionals.
This episode was recoded at ADA - The American Diabetes Association in July 2023.
Real-time real talk is intended for healthcare professionals in the US.
Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.
Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.
Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.
The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.
Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7.
Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products.
A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions.
Dr. Nicholas Argento MD, PhD is a paid spokesperson for Dexcom.
Warning: Do not use the Dexcom G7 CGM System or the Dexcom G6 System if you are on dialysis. The performance of these CGM systems has not been evaluated in this population and sensor readings may be inaccurate.
Brief Safety Statement
BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.
Dexcom Clarity Safety Information
The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.
Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.
References:
1. Breton MD, Kovatchev BP. One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology. Diabetes Technol Ther. 2021 Sep;23(9):601-608. doi: 10.1089/dia.2021.0097. Epub 2021 Apr 21. PMID: 33784196; PMCID: PMC8501470.
2. Tadej Battelino, et al; Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 1 August 2019; 42 (8): 1593–1603. https://doi.org/10.2337/dci19-0028